(+/-)-5,5'-dibenzyl-6,6',7,7'-tetrahydroxy-3,3'-dimethyl-2,2'-binaphthyl1,1',4,4'-tetraone | 1256724-10-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: (+/-)-5,5'-dibenzyl-6,6',7,7'-tetrahydroxy-3,3'-dimethyl-2,2'-binaphthyl1,1',4,4'-tetraone
• 英文别名: BI112D1
• CAS: 1256724-10-3
• 化学式: C₃₆H₂₆O₈
• 分子量: 586.598
• InChiKey: IEJPMWKHSOLTHK-UHFFFAOYSA-N

物化性质

• 沸点：
  892.2±65.0 °C(Predicted)
• 密度：
  1.454±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  5.78
• 重原子数：
  44.0
• 可旋转键数：
  5.0
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  149.2
• 氢给体数：
  4.0
• 氢受体数：
  8.0

反应信息

• 作为产物：
  描述：

  5,5'-dibenzyl-3,3'-dimethyl-2,2'-binaphthyl-1,1',6,6',7,7'-hexaol 在 iron(III) chloride 、 溶剂黄146 、 硫酸 作用下， 以 水 、 丙酮 为溶剂， 以55%的产率得到(+/-)-5,5'-dibenzyl-6,6',7,7'-tetrahydroxy-3,3'-dimethyl-2,2'-binaphthyl1,1',4,4'-tetraone
  参考文献：
  名称：

  作为抗凋亡 B 细胞淋巴瘤/白血病-2 (Bcl-2) 家族蛋白的泛活性抑制剂的阿朴棉酚酮衍生物的合成和生物学评价

  摘要：

  抗凋亡 Bcl-2 家族蛋白的过度表达通常与肿瘤维持、进展和化学抗性有关。抑制这些抗凋亡蛋白是一种有吸引力的癌症治疗方法。在核磁共振 (NMR) 结合测定的指导下，合成了一系列 5,5' 取代的化合物6a (Apogossypolone) 衍生物，并鉴定了抗凋亡 Bcl-2 家族蛋白的泛活性拮抗剂，结合效力在低微摩尔至纳摩尔范围。化合物6f抑制 BH3 肽与 Bcl-X L、Bcl-2 和 Mcl-1 的结合，IC 50值分别为 3.10、3.12 和 2.05 μM。在细胞测定中，6f以剂量依赖性方式有效抑制几种人类癌细胞系中的细胞生长。化合物6f进一步在转基因小鼠中显示出体内功效，并在 PPC-1 小鼠异种移植模型中显示出优异的单药抗肿瘤功效。连同其可忽略不计的毒性，化合物6f代表了一种有前景的药物先导，用于开发基于细胞凋亡的新型癌症疗法。

  DOI：

  10.1021/jm100746q

文献信息

• APOGOSSYPOLONE DERIVATIVES AS ANTICANCER AGENTS
  申请人：Pellecchia Maurizio

  公开号：US20110112112A1

  公开（公告）日：2011-05-12

  The disclosure provides compounds and methods of using Apogossypolone derivatives for treating diseases and disorders. In particular, the disclosure provides compounds of Formula I: or a pharmaceutically acceptable salt, hydrate, or solvate thereof, and provides methods for the preparation of compounds of Formula I; and methods for treating cancer, autoimmune diseases, and inflammation by administering a compound of Formula I.

  本公开提供了使用Apogossypolone衍生物治疗疾病和疾病的化合物和方法。具体而言，本公开提供了式I的化合物：或其药学上可接受的盐，水合物或溶剂和制备式I化合物的方法；以及通过给予式I化合物治疗癌症，自身免疫性疾病和炎症的方法。
• Chemical entities that kill senescent cells for use in treating age-related disease
  申请人：Unity Biotechnology, Inc.

  公开号：US10195213B2

  公开（公告）日：2019-02-05

  Disclosed herein are compounds that are effective for treatment of various disease states associated with senescence. The disclosed compounds can be used to eliminate senescent cells for disease treatment. The dosing of the compounds includes both single administration and regimens of cycling dosages.

  本文公开的化合物可有效治疗与衰老有关的各种疾病状态。所公开的化合物可用于消除衰老细胞以治疗疾病。化合物的给药方式包括单次给药和循环给药。
• COMPOUNDS AND THERAPEUTIC USES
  申请人：Unity Biotechnology, Inc.

  公开号：US20170281649A1

  公开（公告）日：2017-10-05

  Disclosed herein are compounds that are effective for treatment of various disease states associated with senescence. The disclosed compounds can be used to eliminate senescent cells for disease treatment. The dosing of the compounds includes both single administration and regimens of cycling dosages.
• Killing Senescent Cells And Treating Senescence-Associated Conditions Using A Bcl Inhibitor And An Mcl-1 Inhibitor
  申请人：Unity Biotechnology, Inc.

  公开号：US20210379078A1

  公开（公告）日：2021-12-09

  This invention is based on the discovery that inhibiting more than one pathway in senescent cells leading to apoptosis has a profound effect: namely, increasing the potency or the cell specificity of the therapy. Combining a Bcl inhibitor with an Mcl 1 inhibitor increases the ability of the Bcl inhibitor to remove senescent cells from the site of an adverse condition synergistically. This increases the types of senescent cells that can be targeted, broadens the therapeutic range, and allows the user to tailor a particular combination of agents by adjusting the molar ratio for the patient being treated. Suitable indications for treatment may include any condition thought to be mediated at least in part by senescent cells, such as ophthalmic conditions, pulmonary conditions, and atherosclerosis.
• US8937193B2
  申请人：——

  公开号：US8937193B2

  公开（公告）日：2015-01-20